The Zhitong Finance App learned that according to the Hong Kong Stock Exchange's disclosure on September 3, Shenzhen Xinlitai Pharmaceutical Co., Ltd. (abbreviation: Xinlitai, 002294.SZ) submitted a listing application to the main board of the Hong Kong Stock Exchange, with Goldman Sachs, Citibank, and CITIC Securities as co-sponsors. The company submitted its listing to the Hong Kong Stock Exchange on February 12. According to the prospectus, Xinlitai is a leading pharmaceutical company in China focusing on the treatment of cardiovascular-kidney-metabolic (cardio-renal metabolic syndrome) diseases. It is mainly engaged in R&D, production and sales of pharmaceuticals and medical devices. According to Frost & Sullivan's data, in terms of in-hospital sales revenue of cardiovascular medicine in China, the company ranked second in 2025, with a market share of 11.3%.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.